SNIPER(ABL)-39

N/A

Report date: 2022/09/19 15:14:02
NME

Base Information

Drug NameSNIPER(ABL)-39
Drug Alias NameSNIPER(ABL)-39
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionProteolysis
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid, Chronic-Phase
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceuticals International, Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals International, Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Chronic-Phase
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A